![5-Year Follow-Up of COMBI-AD Confirms Long-Term RFS Benefit With Dabrafenib/Trametinib in BRAF+ Melanoma 5-Year Follow-Up of COMBI-AD Confirms Long-Term RFS Benefit With Dabrafenib/Trametinib in BRAF+ Melanoma](https://cdn.sanity.io/images/0vv8moc6/onclive/594c70cb8e7a7d03f25f3034842de9eb8fc5f8ad-200x276.jpg?fit=crop&auto=format)
5-Year Follow-Up of COMBI-AD Confirms Long-Term RFS Benefit With Dabrafenib/Trametinib in BRAF+ Melanoma
![Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial - The Lancet Oncology Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/7cc41765-9b76-4218-8b29-b4f44f4c6217/gr1a_lrg.jpg)
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial - The Lancet Oncology
![Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial - The Lancet Oncology Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/09dff7e8-70c5-4ce6-b59d-ad98d079e1a8/gr1b_lrg.jpg)
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial - The Lancet Oncology
![Sayed ali on Twitter: "Updated adj D and T COMBI AD .29% patient discontinued treatment. #WMC2017 #melanoma #melanoma2017 https://t.co/kbx3i5Esgm" / Twitter Sayed ali on Twitter: "Updated adj D and T COMBI AD .29% patient discontinued treatment. #WMC2017 #melanoma #melanoma2017 https://t.co/kbx3i5Esgm" / Twitter](https://pbs.twimg.com/media/DMnbkbqUMAAtNUH.jpg)
Sayed ali on Twitter: "Updated adj D and T COMBI AD .29% patient discontinued treatment. #WMC2017 #melanoma #melanoma2017 https://t.co/kbx3i5Esgm" / Twitter
![Suplemento Vitamínico Combi AD sabor Framboesa 30ml - Farmácias Unipreço - Suplemento Vitamínico Combi AD sabor Framboesa 30ml - ACHE Suplemento Vitamínico Combi AD sabor Framboesa 30ml - Farmácias Unipreço - Suplemento Vitamínico Combi AD sabor Framboesa 30ml - ACHE](https://d225afdvrjsxie.cloudfront.net/Custom/Content/Products/63/13/63138_suplemento-vitaminico-combi-adulto-sabor-framboesa-30ml_s1_637704096265239835.jpg)
Suplemento Vitamínico Combi AD sabor Framboesa 30ml - Farmácias Unipreço - Suplemento Vitamínico Combi AD sabor Framboesa 30ml - ACHE
![ESMO 2017: COMBI-AD: Adjuvant Dabrafenib (D) Plus Trametinib (T) for Resected Stage III BRAF V600E/K–Mutant Melanoma ESMO 2017: COMBI-AD: Adjuvant Dabrafenib (D) Plus Trametinib (T) for Resected Stage III BRAF V600E/K–Mutant Melanoma](https://larvolclin.s3.us-west-2.amazonaws.com/resize_1675945654188455330663e4e6b6ddc83.jpg)
ESMO 2017: COMBI-AD: Adjuvant Dabrafenib (D) Plus Trametinib (T) for Resected Stage III BRAF V600E/K–Mutant Melanoma
![Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial - The Lancet Oncology Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/f7a9f75d-f26b-4cf0-895e-cee1a4ae002b/gr2_lrg.jpg)
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial - The Lancet Oncology
![Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial - The Lancet Oncology Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/a96cc3d3-9792-4664-8a9d-ee4d3a3ecae1/gr3.jpg)